Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neramexane in subjective tinnitus
NCT00405886Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2005
- Primary completion
- Mar 2007
- Countries
- 2
- Sponsor
- Merz
- Modality
- Small Molecules
- Drugs
- neramexane
- Conditions
- tinnitus
01
Overview
Phase 2, randomised, double-blind trial of neramexane in tinnitus (4 arms), sponsored by Merz. Primary endpoints: Change from baseline in tinnitus severity at 16 weeks and Comparison of adverse events at 20 weeks. Started Oct 2005; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Neramexane 25mg/d
Neramexane 25mg daily
Neramexane 50mg/d
Neramexane 50mg daily
Neramexane 75mg/d
Neramexane 75mg daily
Placebo
Placebo tablets
03
Endpoints
Primary
Change from baseline in tinnitus severity
Comparison of adverse events
Beyond the preview
Go deeper on NCT00405886.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405886.